Stock Events

Stock Events

Kala Bio 

$0.8401
75
-$0.06-6.66% 20:00 Today
+$0.02+2%21:39After hours

Statistics

Day High
0.9585
Day Low
0.823
52W High
1,030
52W Low
0.59
Volume
63,209
Avg. Volume
135,517
Mkt Cap
16.25M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
Next
-8.5
-6
-3.51
-1.01
Expected EPS
-6
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-26.98MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KALA. It's not an investment recommendation.
Tesla
10
TSLA
Apple
9
AAPL
Amazon
9
AMZN
NVIDIA
9
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals competes in the ophthalmology space with treatments for eye diseases, directly competing with Kala's eye care products.
Novartis
NVS
Mkt Cap286.78B
Novartis offers a range of eye care medications, including treatments for conditions that Kala Bio targets, making them a direct competitor.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie, through its acquisition of Allergan, has a strong presence in the ophthalmology market, competing with Kala Bio's eye care solutions.
Bausch Health Companies
BHC
Mkt Cap2.43B
Bausch Health Companies, formerly Valeant Pharmaceuticals, has a significant portfolio in eye health, competing in the same market as Kala Bio.
Biogen
BIIB
Mkt Cap31B
Biogen has a focus on specialty care and biologics that could compete with Kala Bio's treatments in certain niche markets.
Regenxbio
RGNX
Mkt Cap710.63M
REGENXBIO is a biotechnology company focused on the development of gene therapies for eye diseases, directly competing with Kala Bio's approach to eye care.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences, while primarily known for its work in antiviral drugs, has ventured into other therapeutic areas that could potentially compete with Kala Bio's niche markets.

About

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Show more...
CEO
Avi Minkowitz
Employees
6
Country
United States
ISIN
US4831193010
WKN
000A4243T

Listings

F
DE
27F.F
XNAS
US
KALA
LSE
GB
0JQ2.LSE
BOATS
BOATS
KALA.BOATS

0 Comments

Share your thoughts

FAQ

What is Kala Bio stock price today?▼
The current price of KALA is $0.84 USD — it has decreased by -6.66% in the past 24 hours. Watch Kala Bio stock price performance more closely on the chart.
What is Kala Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Kala Bio stocks are traded under the ticker KALA.
Is Kala Bio stock price growing?▼
KALA stock has fallen by -9.08% compared to the previous week, the month change is a +12.01% rise, over the last year Kala Bio has showed a -99.8% decrease.
What is Kala Bio market cap?▼
Today Kala Bio has the market capitalization of 16.25M
When is the next Kala Bio earnings date?▼
Kala Bio is going to release the next earnings report on November 10, 2026.
What is Kala Bio revenue for the last year?▼
Kala Bio revenue for the last year amounts to 0 USD.
What is Kala Bio net income for the last year?▼
KALA net income for the last year is -26.98M USD.
How many employees does Kala Bio have?▼
As of August 20, 2026, the company has 6 employees.
In which sector is Kala Bio located?▼
Kala Bio operates in the Health & Wellness sector.
When did Kala Bio complete a stock split?▼
The last stock split for Kala Bio was on May 11, 2026 with a ratio of 1:50.
Where is Kala Bio headquartered?▼
Kala Bio is headquartered in ARLINGTON, United States.